Abemaciclib, aromatase inhibitor, Eli Lilly et Company, endocrinarum Lorem, Tamoxifen, Verzenio
Abemaciclib cum therapia endocrina comprobatur FDA in HER 2 carcinomate positivo
Martii 2023 : Abemaciclib (Verzenio, Eli Lilly and Company) et therapia endocrina (tamoxifen vel inhibitor aromatasi) approbata sunt ab Administratione Cibus et medicamentis (FDA) ad curationem patientium adultorum cum adjuvante .
CAR T Cell Lorem iudiciis, Glioblastoma, glioblastoma iudiciis, gliomas
Salus et efficacia Studium Anti-B7-H3 CAR-T Cell Therapy ad Glioblastoma recurrentem.
March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" design is used to determine Maximum..
American Supplementum, Carteyva, Sinis, JW Therapeutics, relmacabtagen autoleucel
JW Therapeutica munera Ultimae Fusce Data in Carteyva® in Follicularis Lymphoma et Mantella Cell Lymphoma apud 64 ASH Annuum Conventum
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
dMMR, Dostarlimab-gxly, Pharma, Jemperli
Dostarlimab-gxly approbatur a FDA pro dMMR cancer endometrialis
Feb 2023 : Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) probata est FDA cura aegros adultos cum reparatione deficientis mismatch (dMMR) recurrentes vel cancri endometriali progressi, qui durante vel post priorem .
Daiichi Sankyo, DESTINY-Breast04, Enhertu, fam-trastuzumab deruxtecan-nxki
Fam-trastuzumab deruxtecan-nxki approbatur a FDA pro HER2-low cancer
Augusti 2022: Pro aegros adultis cum HER2-low (IHC 1+ vel IHC 2+/ISH) irresectibilibus vel metastaticis (IHC XNUMX+ vel IHC XNUMX+/ISH) cancer pectoris qui prior chemotherapy in occasu metastatica accepit vel morbum recurrentem per sex vel intra sex expertus est.
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, Olympiae
Olaparib probatus est ad adjuvandum curationem summi periculi primo carcinomate pectoris
Martii 2022: Cibus et medicamentum Administrationis olaparib (Lynparza, AstraZeneca pharmaceutica, LP) approbavit ad curationem aegrorum adultorum cum deletis vel suspectis multiplicibus germlines BRCA-mutatis (gBRCAm) h.
Atezolizumab, Bevacizumab, niveumab, Regorafenib, Stivarga, Tecentriq
Medicamenta ad curationem carcinomatis hepatis probati
Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug. Atezolizumab Avastin (Bevacizumab) Bevacizumab Cabometyx (Cabozantinib-S-M..
FDA, KRAS G12C, Lumakras, NSCLC, sotorasib
FDA probavit primum theraphim iaculis in pulmonis mutatione cancri, quae antea medicamento repugnans esse putabatur
August XX, MMXXI Nuper in May, MMXXI Lumakras (sotorasib) probatus est a US Cibus et medicamentis Administration ut primum adultus et curatio pulmonis cancer aegris est non-parva cellula quae unum subiret, certe ratio prior ..
KEYTRUDA, Merck Poland, NCT02362594, Pembrolizumab, RECIST, USFDA
Probatus per FDA in adjuvant curatio Pembrolizumab est melanoma
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..
Ablynx, ADAMTS13, CABLIVI, caplacizumab yhdp,, FDA, Lorem immunosuppressive, USFDA
Probatus per FDA-Caplacizumab yhdp
In February VI, MMXIX in conjunction per commutationem plasma et immunosuppressive curatio Cibus et medicamentis Administration approbata, caplacizumab yhdp (CABLIVI, Ablynx NV) adultus est acquiritur cum aegris thrombotic thrombocytopeni ..